Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

Caroline Robert, Bogusława Karaszewska, Jacob Schachter, Piotr Rutkowski, Andrzej Maćkiewicz, D. Stroiakovski, M. Lichinitser, Reinhard Dummer, Florent Grange, Laurent Mortier, Vanna Chiarion‐Sileni, Kamil Drucis, Ivana Krajsová, Axel Hauschild, Paul Lorigan, Pascal Wolter, Georgina V. Long, Keith T. Flaherty, Paul Nathan, Antoni Ribas, Anne-Marie Martin, Peng Sun, Wendy Crist, Jeff Legos, Stephen D. Rubin, Shonda M Little, Dirk Schadendorf

New England Journal of Medicine, 2014

Inserm, Institut Gustave Roussy, Sheba Medical Center, The Maria Sklodowska-Curie National Research Institute of Oncology, Poznan University of Medical Sciences, Moscow City Oncology Hospital №62, Essen University Hospital, Russian Cancer Research Center NN Blokhin, University of Zurich, Université de Reims Champagne-Ardenne, Hôpital Robert-Debré, Centre Hospitalier Universitaire de Reims, Hôpital Claude Huriez, Istituto Oncologico Veneto, General University Hospital in Prague, University Hospital Schleswig-Holstein, Universitäts Hautklinik Kiel, University of Lübeck, The Christie NHS Foundation Trust, Melanoma Institute Australia, University of Sydney, Mater Health Services, Massachusetts General Hospital, Mount Vernon Cancer Centre, UCLA Jonsson Comprehensive Cancer Center, GlaxoSmithKline (United States)

View Free PDF Publisher Website

Abstract

This research paper explore the methodology and findings associated with New England Journal of Medicine. The study delves into the core aspects of the research field, providing significant data and citation impact. (Full abstract processing is available via the OpenAlex API).

2632

Citations

View on Google Scholar

Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

Abstract

Journal Details

Join JournalsHub

Welcome Back